U.S. markets closed

GenMark Diagnostics, Inc. (GNMK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.42-0.27 (-2.13%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close12.69
Open12.72
Bid12.36 x 1800
Ask12.36 x 1200
Day's Range12.15 - 12.80
52 Week Range3.36 - 20.88
Volume1,065,691
Avg. Volume1,102,146
Market Cap890.775M
Beta (5Y Monthly)3.27
PE Ratio (TTM)N/A
EPS (TTM)-0.39
Earnings DateOct 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum
    GlobeNewswire

    GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum

    CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTech & Diagnostics Forum. GenMark’s management team is scheduled to present in a virtual setting on Thursday, November 19th, 2020 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com.ABOUT GENMARKGenMark is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections.  For more information, visit www.genmarkdx.com.Investor Relations Contact Leigh Salvo (415) 937-5404 ir@genmarkdx.com

  • GenMark Diagnostics, Inc. (NASDAQ:GNMK) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
    Simply Wall St.

    GenMark Diagnostics, Inc. (NASDAQ:GNMK) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

    As you might know, GenMark Diagnostics, Inc. (NASDAQ:GNMK) just kicked off its latest third-quarter results with some...

  • GenMark Diagnostics Inc (GNMK) Q3 2020 Earnings Call Transcript
    Motley Fool

    GenMark Diagnostics Inc (GNMK) Q3 2020 Earnings Call Transcript

    Please note that this call is being recorded today, Wednesday, October 28, 2020 at 1:30 PM Pacific Time and that will be available on the Investors section of GenMark's website at www.genmarkdx.com. Before we begin, I would like to inform you that certain statements made by GenMark during the course of this call may constitute forward-looking statements. Any statement about our expectations, beliefs, plans, objectives, assumptions or future events or performance are forward-looking statements.